Blinded experiment

In a blind or blinded experiment, information that could influence participants or investigators is withheld until the experiment is completed. Blinding is used to reduce or eliminate potential sources of bias, such as participants’ expectations, the observer-expectancy effect, observer bias, confirmation bias, and other cognitive or procedural influences.

Blinding can be applied to different participants in an experiment, including study subjects, researchers, technicians, data analysts, and outcome assessors. When multiple groups are blinded simultaneously (for example, both participants and researchers), the design is referred to as a double-blind study.

In some cases, blinding is desirable but impractical or unethical. For example, it is not possible to blind a participant receiving a physical therapy intervention, or a surgeon performing an operative procedure. Well-designed clinical protocols therefore aim to maximize the effectiveness of blinding within ethical and practical constraints.

During the course of an experiment, a participant becomes unblinded if they deduce or otherwise obtain information that has been masked to them. For example, a patient who experiences a side effect may correctly guess their treatment, becoming unblinded. Unblinding is common in blinded experiments, particularly in pharmacological trials. In particular, trials on pain medication and antidepressants are poorly blinded. Unblinding that occurs before the conclusion of a study is a source of experimental error, as the bias that was eliminated by blinding is re-introduced. The CONSORT reporting guidelines recommend that all studies assess and report unblinding. In practice, very few studies do so.

Blinding is an important tool of the scientific method, and is used in many fields of research. In some fields, such as medicine, it is considered essential. In clinical research, a trial that is not blinded is called an open trial.